Background Myocardial injury, as reflected by elevated cardiac troponin levels in plasma, is common in
Background
Patients hospitalized for community-acquired pneumonia (CAP) are prone to develop complications such as myocardial infarction, cardiac arrhythmias, and congestive heart failure [1] [2] [3] . All of these adverse cardiovascular events pose a risk for both short-term and long-term mortality [3, 4] . In this context, several risk factors have been described, most importantly advanced age, pre-existing cardiovascular morbidity and acute pneumonia severity [5, 6] . However, one cardiac complication that has received far less attention is the occurrence of 'silent' myocardial injury. A handful of reports have shown that CAP can be associated with high plasma cardiac troponin levels without symptoms of myocardial infarction [7] , and that these elevations are related to increased mortality [8, 9] .
Unfortunately, most studies have relied on cardiac troponin measurements that were ordered on clinical indication (introducing information bias) or solely performed upon intensive care unit (ICU) admission (limiting temporal resolution) [7] [8] [9] . As a result, there is currently a lack of knowledge regarding the true incidence of myocardial injury as well as the dynamics of cardiac troponin release over time. Likewise, only limited information is available about risk factors for troponin release, as most previous studies have focused on baseline predictors and were unable to assess whether and when a rise or fall in troponin occurred [7] [8] [9] . With the current study we aimed to provide a more detailed description of the clinical settings during which troponin release occurs in patients admitted to the ICU with severe CAP in order to identify (1) patient-level risk factors for the development of myocardial injury, and (2) time-dependent risk factors affecting the daily rise and/or fall of troponin levels during ICU stay.
Methods

Study design
This study was part of the Molecular Diagnosis and Risk Stratification of Sepsis project, an observational cohort study in the mixed ICUs of two tertiary centers in The Netherlands. The institutional review boards of both hospitals approved an opt-out method for obtaining consent and approved the current study (protocol numbers 10-056C and 15-232). We included consecutive patients with severe CAP admitted between January 2011 and May 2015. The post-hoc likelihood of infection had to be rated at least probable according to strict criteria, as previously described in detail [10] . In summary, all patients required both a high clinical suspicion of pneumonia and clear radiographic evidence of new or progressive pulmonary consolidations. Patients were excluded if the clinical onset of pneumonia had occurred more than 48 hours before ICU admission. We also excluded patients following cardiopulmonary resuscitation prior to ICU admission, patients not meeting organ failure criteria as described in detail previously [11] , and patients who had been transferred from other hospitals.
Data collection
We identified potential risk factors of troponin release through a search of the literature [3, 5, 6, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and classified them according the following clusters: (A) patient-level risk factors present at baseline, and (B) three categories of time-dependent risk factors: (1) markers of inflammation and coagulation, (2) determinants of myocardial oxygen supply-demand mismatch, and (3) other potential causes of troponin release. All patient-level and most time-dependent risk factors had been prospectively recorded within the MARS study, yet some required additional retrospective review of the medical chart in order to yield accurate classifications. A complete list of all risk factors studied and their definitions can be found in table S1 (supplementary material). Additionally, in the event that troponin release had been clinically recognized, we recorded the results of cardiac diagnostic procedures (such as ECG and echocardiography) and any therapeutic interventions that were subsequently initiated.
Troponin measurements and outcome definitions
We measured high-sensitivity cardiac troponin I (hs-cTnI) in heparinized plasma samples collected daily during the first week in ICU (Abbott ARCHITECT STAT High Sensitive Troponin-I, Abbott Diagnostics, Chicago, IL, USA). The upper reference limit for the hs-cTnI assay was 26 ng/L [23] . Patients with no available plasma samples were excluded. All observation days during the first week in ICU were classified into one of the following three categories: (1) no troponin release, (2) possible troponin release, or (3) definite troponin release. An ICU day was categorized as no troponin release if it was followed by a hs-cTnI concentration constituting both an absolute decrease of > 26 ng/L and a relative decrease >40% from a prior measurement, or any value below the upper reference limit of 26 ng/L. An ICU day was categorized as definite troponin release if it was followed by a value constituting both an absolute hs-cTnI increase of >26 ng/L and relative increase of >40%. All days not fulfilling these definitions were categorized as possible troponin release. In addition, patients were grouped according to release pattern, based on a visual inspection of troponin trajectories.
Statistical analysis
We fitted multivariable models in order to assess (1) the association between baseline risk factors and hs-cTnI concentrations on ICU admission, and (2) the relation between time-dependent risk factors and daily changes in hs-cTnI concentrations during the first week of ICU stay. For model one we used linear regression analysis, with hs-cTnI measured on day 1 as the dependent variable, and with all baseline risk factors as covariates. For model two we used linear mixed-effects regression analysis, with hs-cTnI concentration on day X+1 as the dependent variable conditional on the hs-cTnI value on day X, thereby effectively modelling daily changes in troponin. A random intercept was included to account for the correlation between repeated measurements. As covariates, the model initially included all risk factors in table S1 (Supplementary material). However, we subsequently excluded variables showing evidence of multicollinearity or having a very low observed incidence (≤1%). To facilitate interpretation of the models, all beta-coefficients are expressed on a scale that reflects the percentage change in hs-cTnI level on subsequent days (with corresponding 95% confidence interval) per unit increase in each predictor variable. Missing data were handled by multiple imputation. Details on the multivariable models, study definitions, and imputation procedure can be found in the additional file (Supplementary material: supplemental methods). Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC,
USA) or R version 3.2.2 (R Foundation for Statistical Computing, 2015).
Results
Among 388 consecutive CAP patients treated during the years of enrolment, 200 were eligible for study inclusion (figure 1). A total of 20 subjects were excluded because of missing plasma samples and one patient because electronic health records were unavailable due to technical issues, leaving 179 (90%) patients with a total of 792 observation days during the first week in ICU for analysis. Upon first presentation to the ICU, hs-cTnI levels >26 ng/L were observed in 130 (73%) subjects. An additional 22 (12%) patients who entered the ICU having normal troponin values demonstrated troponin release during subsequent days in ICU. Overall, elevated troponin levels were observed on 499 (63%) of the 792 ICU days studied.
Troponin release patterns
A total of 152 patients (ever) had troponin release during their first week in ICU, with 148 (97%) elevations occurring within the first 4 days. Maximum plasma concentrations were observed on day 1 in 78 (51%) of these cases, and 124 (82%) of subjects reached their peak before day 4. 
Clinical management of troponin release
Among the 152 patients with troponin release, only a minority of 45 (30%) subjects had their troponin measured by the treating physicians and were thus clinically recognized. Further diagnostic tests that were subsequently ordered included echocardiography in 19 (42%) and full 12-lead ECG in 29 (64%) subjects, with the latter revealing signs of myocardial ischemia in 16 (55%) cases. Clinical management usually amounted to a 'wait and see' policy, consisting of successive troponin measurements and clinical monitoring. In 19 of the 45 patients (42%) with clinically recognized myocardial injury a cardiologist was consulted, and antiplatelet or anticoagulant therapy was initiated in 9 subjects (20%).
Patient-level (baseline) risk factors for troponin release
Patients with elevated hs-cTnI plasma concentrations on admission were older and more frequently had a history of coronary artery and peripheral vascular disease than those with normal hs-cTnI levels (table   1) . In addition, patients with myocardial injury had higher acute physiology and chronic health evaluation (APACHE) IV scores (indicating greater disease severity), yet their 30-day mortality rate was not different. Figure 3 shows the results of the multivariable linear model. After adjustment the following risk factors remained independently associated with increased hs-cTnI levels upon ICU admission: coronary artery disease (160% increase, 95% CI 7-529, p-value 0.03), smoking (304% increase, 95% CI 59-924, p-value 0.003), and higher APACHE IV scores (2% increase, 95% CI 0.7-3.3, p-value 0.002). The presence of S. aureus as causative pathogen was associated with reduced hs-cTnI levels on ICU admission compared to other pathogens (67% reduction, 95% CI 9-88, p-value 0.03).
Time-dependent (daily) risk factors for troponin release
Crude comparisons revealed lower platelet counts and prolonged prothrombin times on the days when troponin release occurred, suggesting an increased activation of the coagulation system (table 2) . In addition, we observed more hypotension, shock, a greater use of catecholamines, and anemia on such days, suggesting a myocardial oxygen supply-demand mismatch. The incidence of alternative (non sepsis-related) diagnoses that may explain troponin release, such as stroke, peri-/myocarditis, rhabdomyolysis, pulmonary hypertension, circulatory arrest, and cardiac contusion, was low. However, acute kidney injury was more prevalent on days with troponin release, whereas the use of antiplatelet drugs and macrolide antibiotics seemed to protect against this. 
Discussion
We systematically measured daily plasma concentrations of troponin during a week following onset of severe CAP and observed evidence of myocardial injury in a large majority (85%) of patients. Almost all cases of troponin release became evident within the first 4 days. Patient characteristics associated with troponin release at ICU admission included smoking and coronary artery disease, whereas
Staphylococcus aureus as a primary causative pathogen of pneumonia seemed to protect against this.
More importantly, an analysis of time-dependent factors associated with the daily rise and fall of troponin levels pointed towards activated coagulation and myocardial oxygen supply-demand mismatch as the most likely causes of myocardial injury.
Previous studies in CAP patients have reported apparent incidences of troponin release between 19% and 58% [8, 9, 24] , which is considerably lower than what we observed. However, most of these studies did not systematically measure plasma concentrations on a daily basis, used less sensitive troponin assays, and included patients with lower severity of disease than we did. The 85% incidence of myocardial injury observed in our study is very similar to rates previously reported by studies that methodically applied troponin screening in patients with severe sepsis (85%) and general critical illness (84%) [25, 26] .
Baseline variables that have previously been identified as possible risk factors for troponin release in CAP patients include advanced age, high disease severity, renal dysfunction, ischemic heart disease, smoking, and the presence of chronic obstructive pulmonary disease, peripheral artery disease, and diabetes [8, 9, 24] . Among these, only a history of coronary artery disease, smoking, and acute disease severity (APACHE) could be confirmed in our study. This might be explained by the fact that many studies did not perform multivariable adjustment [8, 9, 24] , or were conducted in a clinical domain that predominately included non-ICU patients [8, 24] . The observed protective effect of Staphylococcus aureus on hs-cTnI levels represents a novel finding and requires confirmation in future studies.
We are not aware of studies that have investigated time-dependent predictors of cardiac troponin release. In the present study we found that tachycardia, hypotension, dobutamine use, and low platelet counts were associated with increasing hs-cTnI plasma concentrations. This suggests that myocardial oxygen supply-demand mismatch, and possibly an activated coagulation system, are the principal drivers of troponin release during sepsis. The fact that type 2 myocardial ischemia (i.e., related to supply-demand mismatch) rather than type 1 infarction (i.e., related to a primary coronary event)
should be held responsible for myocardial damage in this setting is supported by observations in patients admitted to the ICU with the systemic inflammatory response syndrome (SIRS) or sepsis, in whom troponin release was not associated with abnormalities on coronary angiography or stress echocardiography in the majority of cases [27] . In addition, autopsies performed in patients who succumbed to sepsis revealed no evidence of significant myocardial cell necrosis [28] . A role for activated coagulation in the pathogenesis of myocardial injury during sepsis is supported by results of a previous cohort study in less severe CAP patients, which showed that elevated concentrations of several markers of platelet activation in plasma were associated with the development of myocardial infarction [24] . In contrast, assessment of clot formation using rotational thromboelastometry yielded no differences between hs-cTnI-positive and -negative patients with SIRS, sepsis, or septic shock, although the sample size of 38 subjects provided only limited power to this study [29] .
Median troponin concentrations observed in the current study were similar to those in patients diagnosed with non ST-elevation myocardial infarctions [30] , indicating that CAP patients may suffer serious cardiac injury. Importantly, only 30% of troponin release events in our study were recognized by the treating ICU physicians. Furthermore, a cardiologist was consulted in less than half of these cases, and subsequent clinical management was mostly conservative. This practice reflects our limited understanding of both the underlying etiology and prognostic implications of troponin release during sepsis. Since there are currently no well-defined treatment options, many physicians adopt a pragmatic 'wait and see' approach.
Our study has several limitations. First, we only measured hs-cTnI concentrations in plasma once daily, thereby possibly missing smaller troponin elevations. Second, we did not measure hs-cTnI until the patient arrived in the ICU. As plasma levels followed a declining trajectory in 36% of patients, it is likely that peak troponin concentrations (and any accompanying time-dependent etiologic factors) may not have been correctly detected in all subjects. Third, because of the strict observational nature of our study not all patients underwent a full diagnostic work-up for all possible causes of troponin elevation.
However, given its multicenter design we believe that our study reflects current practice across diverse clinical settings. Finally, we used a complex mixed-effects regression model which should be regarded as exploratory given the large number of predictors for troponin release. Furthermore, the model residuals showed some evidence of non-normality, which may have resulted in increased standard errors and more conservative p-values (see supplementary material for details).
Conclusions
Myocardial injury develops in a large majority of patients with severe CAP and predominantly occurs early during its clinical course. Myocardial oxygen supply-demand mismatch and an activated coagulation system are potential causes of this injury.
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